Lumida
/ERAS
⌘K
Erasca Inc

Erasca Inc

ERAS
$19.17USD+0.79%+0.15 today

MARKET CAP

6.7B

P/E (TTM)

FWD P/E

DAY RANGE

$18 – $20

52W RANGE

$1
$24

AI Summary

Stalk
Buy NowMedium

ERAS remains in a Stage 2 advancing regime with clear higher-highs and higher-lows above rising moving averages, supported by an active Lockout Rally. Price is holding a shallow pullback into the rising 9EMA and 20EMA support zone, and short-term timing favors buying the pullback for momentum continuation.

  • ERAS-0015 targets RAS/MAPK cancers with strong clinical promise
  • 13F ownership shows significant institutional backing
  • Securities class action caused 48% drop and $2.8B market loss
Full analysis →
Insider Trades5 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Apr 1, 2026SellERASEbun GarnerChief Legal Officer160,000$9.05$6.7B-21.05%+1341.25%$1.4M+0.00%10b5-1Buy Now
Mar 4, 2026SellERASShannon MorrisChief Medical Officer40,000$8.37$6.7B-21.05%+1341.25%$334.8K+0.00%10b5-1Buy Now
Dec 15, 2025BuyERASEbun GarnerGeneral Counsel & Corp. Sec.243,902$3.61$6.7B-21.05%+1341.25%$879.5K+0.71%10b5-1Buy Now
Dec 5, 2023BuyERASJonathan E LimChairman & CEO1,000,000$1.70$6.7B-21.05%+1341.25%$1.7M+4.03%Buy Now
Oct 5, 2023BuyERASJonathan E LimChairman & CEO1,000,000$2.03$6.7B-21.05%+1341.25%$2.0M+5.42%Buy Now